About - LLY :

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Employees - 43000, CEO - Mr. David A. Ricks, Sector - Healthcare, Country - US, Market Cap - 738.68B

Altman ZScore(max is 10): 8.5, Piotroski Score(max is 10): 5, Working Capital: $6741000000, Total Assets: $75606900000, Retained Earnings: $13627200000, EBIT: 10844600000, Total Liabilities: $61286200000, Revenue: $40863300000

AryaFin Target Price - $258.35 - Current Price $767.76 - Analyst Target Price $1008.45

Stats & Key Metrics
TickerLLY
IndexS&P 500
Curent Price 767.76
Change1.35%
Market Cap738.68B
Average Volume3.76M
Income8.37B
Sales40.86B
Book Value/Share14.99
Cash/Share3.66
Dividend Est5.34 (0.70%)
Dividend TTM5.20 (0.68%)
Dividend Ex-DateFeb 14, 2025
Employees43000
Moving Avg 20days-2.75%
Moving Avg 50days-6.57%
Moving Avg 200days-8.43%
Shares Outstanding950.22M
Earnings DateOct 30 BMO
Inst. Ownership72.76%
Key Ratios & Margins
Price/Earnings83.99
Forwad P/E33.88
PE Growth2.55
Price/Sales18.08
Price/Book51.23
Price/Cash209.95
Price/FCF527.70
Quick Ratio0.97
Current Ratio1.27
Debt/Equity2.19
Return on Assets12.54%
Return on Equity65.75%
Return on Investment19.34%
Gross Margin80.91%
Ops Margin35.33%
Profit Margin20.48%
RSI40.37
BETA(β)0.41
From 52week Low35.40%
From 52week High-21.06%
Earnings & Valuation
EPS9.14
EPS next Year22.66
EPS next Qtr5.48
EPS this Year108.29%
EPS next 5 Year33.00%
EPS past 5 Year13.74%
Sales past 5 Year9.91%
EPS Y/Y68.88%
Sales Y/Y27.41%
EPS Q/Q1780.56%
Sales Q/Q20.43%
Sales Surprise-5.44%
EPS Surprise-16.97%
ATR(14)23.53
Perf Week-2.71%
Perf Month1.90%
Perf Quarter-16.41%
Perf Year34.65%
Perf YTD31.71%
Target Price1008.45

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer